Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2026-02-10 Fund Information / Fact…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
115年1月營業收入
Fund Information / Factsheet Classification · 95% confidence The document is a brief financial summary showing monthly and cumulative net operating revenue figures for a company named 美時 for January of the 115th year of the Republic of China calendar (equivalent to 2026). It includes percentage changes compared to the previous year and explanatory notes about accounting standards and reporting practices. The document length is only 780 characters, indicating it is a short summary rather than a full financial report. There is no indication of detailed financial statements, management discussion, or comprehensive analysis. This matches the description of a Fund Information / Factsheet (FS), which is a brief summary of key company facts and financials. It is not an announcement of a report, nor a full annual or interim report, nor a regulatory filing. Therefore, the best classification is FS with high confidence.
2026-02-10 Chinese
(補充115/02/03公告)公告本公司人事異動
Board/Management Information Classification · 100% confidence The document is a company announcement regarding a personnel change, specifically the appointment of a new Vice President for Global Business Development. It includes details such as the effective date, the name of the new appointee, and references a prior announcement. There is no financial data, no mention of financial results, reports, or regulatory filings beyond the personnel change. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2026-02-09 Chinese
代子公司公告資金貸與他人超限改善計畫
Regulatory Filings Classification · 95% confidence The document is a short announcement (879 characters) from a listed company (1795 美時) regarding a subsidiary's capital lending exceeding limits and the improvement plan to address it. It references a regulatory letter from the Financial Supervisory Commission and outlines corrective measures. There are no financial statements, detailed financial data, or comprehensive reports included. The document is primarily a regulatory disclosure about a corporate event related to capital lending limits and compliance measures. It does not contain an annual report, audit report, earnings release, or other detailed financial or management reports. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS) rather than a full report or announcement of a report publication.
2026-02-09 Chinese
公告本公司人事異動
Board/Management Information Classification · 100% confidence The document is a short announcement (715 characters) about a personnel change, specifically the appointment of a new Vice President for Global Business Development at the company 美時 (1795). It includes details such as the position, effective date, and the name of the new appointee. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to any report publication. The content clearly fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2026-02-03 Chinese
公告本公司人事異動
Board/Management Information Classification · 100% confidence The document is a short announcement (770 characters) about a personnel change, specifically the appointment of a new Chief Technology Officer (科技長) at the company 美時. It includes details such as the name of the new appointee, the effective date, and the role change. There is no financial data, no mention of financial results, reports, or regulatory filings beyond the personnel change. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2026-02-03 Chinese
說明媒體報導
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company (美時化學製藥股份有限公司) reporting a product recall due to quality issues found during stability testing. It includes details about the recall, regulatory communication, and impact assessment. The document is only 1185 characters long and does not contain any financial statements, detailed financial data, or comprehensive report content. It is a regulatory announcement about a product recall and related compliance, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-01-24 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.